Business Context and Reporting Period
This Form 8-K Current Report was filed by Oramed Pharmaceuticals Inc. on May 1, 2023. The report discloses a corporate governance event: the expansion of the Board of Directors and the appointment of a new director effective May 1, 2023.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the increase in the size of the Board of Directors by one seat. Mr. Benjamin Shapiro was appointed to fill the resulting vacancy. No financial or operational changes were reported in this document.
Management Commentary and Governance Details
- New Director: Mr. Benjamin Shapiro, age 39, was appointed to the Board. He is a co-founder of The Daily Wire and host of "The Ben Shapiro Show."
- Background: Mr. Shapiro holds a B.A. in Political Science from UCLA (summa cum laude) and a law degree from Harvard Law School (cum laude).
- Committee Assignments: The Board has not yet appointed Mr. Shapiro to any specific committees.
- Compensation: Mr. Shapiro will receive fees identical to those of other non-executive directors.
- Indemnification: The Company expects to enter into a standard indemnification agreement with Mr. Shapiro on terms consistent with existing agreements for other directors and officers.
- Conflicts of Interest: The filing states there are no transactions in which Mr. Shapiro has an interest requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Shapiro's appointment (May 1, 2023).
- Confirm the total number of directors on the Board following this expansion.
- Review the Company's standard director fee schedule to understand the specific remuneration amount.
- Monitor future filings for Mr. Shapiro's assignment to specific Board committees.